The expression of matrix degrading enzymes by macrophages and macrophage-derived foam cells in atherosclerotic lesions has been proposed as a mechanism for the release of matrixbound growth factors and plaque destabilization. In this regard, macrophage plasminogen activation plays a central role in extracellular matrix degradation. Plasmin degrades several components of the extracellular matrix and activates a family of matrix-degrading metallo-proteinases. Macrophages localize and regulate plasminogen activation by their expression of a receptor for urokinase-type plasminogen activator (uPA) and several receptors for plasmin (ogen). The identities and regulation of these plasminogen receptors are not completely understood. In preliminary studies, we have demonstrated that annexin II is a constitutive plasmin receptor on murine macrophages and human monocyte-derived macrophages. In addition, we have demonstrated that autoproteolysis of membrane-bound plasmin is another mechanism by which pericellular plasmin is regulated. Following its activation, membrane-bound plasmin is proteolyzed into fragments with disparate physiologic properties. Partial NH2- terminal sequence of an enzymatically inactive 48 kDa plamin fragment, found in macrophage conditioned media and bound to cells, indicates that it comprises the entire sequence of angiostatin, a recently described inhibitor of endothelial cell proliferation and angiogenesis. The overall aims of studies proposed in this application are to: determine the regulation of pericellular proteolysis of plasmin and its consequences on macrophage function; determine whether proteolysis of membrane-bound plasmin generates fragments of plasmin expressing angiostatin activity; characterize macrophage and foam cell plasminogen receptors; and correlate aortic uPA and uPA receptor expression with lesion development in apoE-deficient mice. Result of these studies will help to elucidate the mechanisms by which macrophages orchestrate tissue remodeling and may provide us with novel interventional strategies for the treatment of atherosclerosis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
5P50HL056987-05
Application #
6442297
Study Section
Project Start
2001-04-01
Project End
2003-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
2001
Total Cost
$280,718
Indirect Cost
Name
Weill Medical College of Cornell University
Department
Type
DUNS #
201373169
City
New York
State
NY
Country
United States
Zip Code
10065
Gagarin, Dmitry; Yang, Zhaoqing; Butler, Jason et al. (2005) Genomic profiling of acquired resistance to apoptosis in cells derived from human atherosclerotic lesions: potential role of STATs, cyclinD1, BAD, and Bcl-XL. J Mol Cell Cardiol 39:453-65
Hyer, Jeanette; Kuhlman, Julie; Afif, Evelyn et al. (2003) Optic cup morphogenesis requires pre-lens ectoderm but not lens differentiation. Dev Biol 259:351-63
Kelly, Kristine A; Wei, Yan; Mikawa, Takashi (2002) Cell death along the embryo midline regulates left-right sidedness. Dev Dyn 224:238-44
Han, Jihong; Hajjar, David P; Zhou, Xiaoye et al. (2002) Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J Biol Chem 277:23582-6
Takebayashi-Suzuki, K; Pauliks, L B; Eltsefon, Y et al. (2001) Purkinje fibers of the avian heart express a myogenic transcription factor program distinct from cardiac and skeletal muscle. Dev Biol 234:390-401
Han, J; Nicholson, A C; Zhou, X et al. (2001) Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I. J Biol Chem 276:16567-72
Feng, J; Han, J; Pearce, S F et al. (2000) Induction of CD36 expression by oxidized LDL and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR-gamma. J Lipid Res 41:688-96
Takebayashi-Suzuki, K; Yanagisawa, M; Gourdie, R G et al. (2000) In vivo induction of cardiac Purkinje fiber differentiation by coexpression of preproendothelin-1 and endothelin converting enzyme-1. Development 127:3523-32
Du, B; Fu, C; Kent, K C et al. (2000) Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-beta type II receptor. J Biol Chem 275:39039-47
Febbraio, M; Podrez, E A; Smith, J D et al. (2000) Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049-56

Showing the most recent 10 out of 24 publications